Roberto Tascione to be new CEO of Zambon
Family-owned Italian pharma company Zambon has appointed Roberto Tascione as its new chief executive to drive the business on a global scale.
Mr Tascione, aged 54 years, has a long experience in the pharmaceutical sector and started his career at Bristol-Myers Squibb Italy, before leading the Primary Care and OTC divisions of Schering Plough. From 2009 to 2014 he was CEO of Gilead Italy and on May 2014 he returned to Bristol-Myers Squibb as president and chief executive Italy. Mr Tascione also served on the general council of Confindustria and was member of Farmindustria Board and the Committee for the Ethical Code.
"Zambon is a leading Italian excellence, with a strong tradition and a strong international outlook dating back to the '50s," said Mr Tascione, adding: “I am very proud to drive the company in this new stage of growth, look at new business opportunities and strengthen our international network."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze